BWAY vs. XAIR, DCTH, ANIK, TMCI, OSUR, CERS, NVRO, SGHT, GUTS, and TCMD
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Beyond Air (XAIR), Delcath Systems (DCTH), Anika Therapeutics (ANIK), Treace Medical Concepts (TMCI), OraSure Technologies (OSUR), Cerus (CERS), Nevro (NVRO), Sight Sciences (SGHT), Fractyl Health (GUTS), and Tactile Systems Technology (TCMD). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay (NASDAQ:BWAY) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
BrainsWay has higher revenue and earnings than Beyond Air. BrainsWay is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Beyond Air has a net margin of 0.00% compared to BrainsWay's net margin of -4.83%. BrainsWay's return on equity of -3.98% beat Beyond Air's return on equity.
BrainsWay received 18 more outperform votes than Beyond Air when rated by MarketBeat users. However, 68.75% of users gave Beyond Air an outperform vote while only 64.58% of users gave BrainsWay an outperform vote.
In the previous week, BrainsWay had 3 more articles in the media than Beyond Air. MarketBeat recorded 4 mentions for BrainsWay and 1 mentions for Beyond Air. BrainsWay's average media sentiment score of 1.53 beat Beyond Air's score of 0.62 indicating that BrainsWay is being referred to more favorably in the media.
BrainsWay currently has a consensus target price of $13.00, suggesting a potential upside of 106.68%. Beyond Air has a consensus target price of $10.75, suggesting a potential upside of 739.84%. Given Beyond Air's stronger consensus rating and higher probable upside, analysts clearly believe Beyond Air is more favorable than BrainsWay.
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 31.5% of Beyond Air shares are held by institutional investors. 19.0% of BrainsWay shares are held by company insiders. Comparatively, 19.0% of Beyond Air shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
BrainsWay has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.
Summary
BrainsWay beats Beyond Air on 9 of the 16 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
